Dore GJ - Search Results

1

Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs.

Larney S, Grebely J, Hickman M, De Angelis D, Dore GJ, Degenhardt L. Larney S, et al. Among authors: dore gj. Int J Drug Policy. 2015 Oct;26(10):950-7. doi: 10.1016/j.drugpo.2015.07.010. Epub 2015 Jul 26. Int J Drug Policy. 2015. PMID: 26297564

2

Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.

Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K, Giles W, Gow P, Kaldor J, Loveday S, Powell E, Spencer J, Wodak A. Law MG, et al. Among authors: dore gj. Int J Epidemiol. 2003 Oct;32(5):717-24. doi: 10.1093/ije/dyg101. Int J Epidemiol. 2003. PMID: 14559738

3

The impact of injecting drug use status on hepatitis C-related referral and treatment.

Stoové MA, Gifford SM, Dore GJ. Stoové MA, et al. Among authors: dore gj. Drug Alcohol Depend. 2005 Jan 7;77(1):81-6. doi: 10.1016/j.drugalcdep.2004.07.002. Drug Alcohol Depend. 2005. PMID: 15607844

4

Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users.

Amin J, Law MG, Micallef J, Jauncey M, Van Beek I, Kaldor JM, Dore GJ. Amin J, et al. Among authors: dore gj. Epidemiol Infect. 2007 Jan;135(1):144-50. doi: 10.1017/S0950268806006388. Epub 2006 May 17. Epidemiol Infect. 2007. PMID: 16707030 Free PMC article.

5

Referral for chronic hepatitis C treatment from a drug dependency treatment setting.

Hallinan R, Byrne A, Agho K, Dore GJ. Hallinan R, et al. Among authors: dore gj. Drug Alcohol Depend. 2007 Apr 17;88(1):49-53. doi: 10.1016/j.drugalcdep.2006.09.018. Epub 2006 Oct 25. Drug Alcohol Depend. 2007. PMID: 17067763

6

High incidence of hepatitis C virus reinfection within a cohort of injecting drug users.

Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, Kaldor JM, White PA, Dore GJ. Micallef JM, et al. Among authors: dore gj. J Viral Hepat. 2007 Jun;14(6):413-8. doi: 10.1111/j.1365-2893.2006.00812.x. J Viral Hepat. 2007. PMID: 17501762

7

Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.

Nguyen OK, Dore GJ, Kaldor JM, Hellard ME; ATAHC Protocol Steering Committee. Nguyen OK, et al. Among authors: dore gj. Int J Drug Policy. 2007 Oct;18(5):447-51. doi: 10.1016/j.drugpo.2007.01.007. Epub 2007 Feb 21. Int J Drug Policy. 2007. PMID: 17854736 Clinical Trial.

8

The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure.

Matthews GV, Grebely J, Dore GJ. Matthews GV, et al. Among authors: dore gj. J Hepatol. 2008 Sep;49(3):305-7. doi: 10.1016/j.jhep.2008.06.005. Epub 2008 Jun 26. J Hepatol. 2008. PMID: 18644647 Free article. No abstract available.

9

Modelling and calibration of the hepatitis C epidemic in Australia.

Razali K, Amin J, Dore GJ, Law MG, HCV Projections Working Group. Razali K, et al. Among authors: dore gj. Stat Methods Med Res. 2009 Jun;18(3):253-70. doi: 10.1177/0962280208094689. Epub 2008 Nov 26. Stat Methods Med Res. 2009. PMID: 19036911

10

HCV reinfection studies and the door to vaccine development.

Grebely J, Thomas DL, Dore GJ. Grebely J, et al. Among authors: dore gj. J Hepatol. 2009 Oct;51(4):628-31. doi: 10.1016/j.jhep.2009.07.002. Epub 2009 Jul 17. J Hepatol. 2009. PMID: 19660823 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

520 results

Search Page